Generated by AI
Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for cancer. The company’s current pipeline centers on its Amphiphile (AMP) platform, which is designed to deliver vaccines, immunomodulators, and adjuvants to the lymph nodes to support a stronger immune response. Its programs include investigational therapies for KRAS-driven cancers, BRAF-driven cancers, and other mutation-defined tumor types, alongside broader efforts in cancer immunotherapy and selected infectious disease applications. Elicio Therapeutics Inc. works at the intersection of oncology and immune system engineering, using platform-based drug design to create both personalized and off-the-shelf candidates for clinically important targets. Headquartered in Boston, Massachusetts, Elicio Therapeutics Inc. is positioned as a specialized player in the biotechnology market with a focus on hard-to-treat cancers and precision immunotherapy approaches.
Website451 D Street
Boston, MA, 02210
United States
The latest articles about ELTX.
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancerAdditional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-ge
Summary of Jul 8's posts. Generated by AI.
Summary of Jun 18's posts. Generated by AI.
No summary yet.
Summary of Jun 18's posts. Generated by AI.
Investors talking about ELTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.